help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takami, M.
Right arrow Articles by Suda, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takami, M.
Right arrow Articles by Suda, T.
Endocrinology Vol. 141, No. 12 4711-4719
Copyright © 2000 by The Endocrine Society

ARTICLES

Intracellular Calcium and Protein Kinase C Mediate Expression of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in Osteoblasts

Masamichi Takami, Naoyuki Takahashi, Nobuyuki Udagawa, Chisato Miyaura, Koji Suda, Je-Tae Woo, T. John Martin, Kazuo Nagai and Tatsuo Suda

Department of Biochemistry, School of Dentistry, Showa University (M.T., N.T., N.U., T.S.), Tokyo 142-8555, Japan; Department of Bioengineering, Tokyo Institute of Technology (K.S., J.-T. W., K.N.), Yokohama 226-8501, Japan; Department of Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Science (C.M.), Tokyo 192-0392, Japan; and St. Vincent’s Institute of Medical Research (T.J.M.), Fitzroy, Victoria 3065, Australia

Address all correspondence and requests for reprints to: Dr. Tatsuo Suda, Department of Biochemistry, School of Dentistry, Showa University, 1–5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan. E-mail: suda{at}dent.showa-u.ac.jp

Receptor activator of nuclear factor-{kappa}B ligand (RANKL) and osteoprotegerin (OPG) produced by osteoblasts/stromal cells are involved as positive and negative regulators in osteoclast formation. Three independent signals have been proposed to induce RANKL expression in osteoblasts/stromal cells: vitamin D receptor-, cAMP-, and gp130-mediated signals. We previously reported that intracellular calcium-elevating compounds such as ionomycin, cyclopiazonic acid, and thapsigargin induced osteoclast formation in cocultures of mouse bone marrow cells and primary osteoblasts. Increases in calcium concentration in culture medium also induced osteoclast formation in cocultures. Treatment of primary osteoblasts with these compounds or with high calcium medium stimulated the expression of both RANKL and OPG messenger RNAs (mRNAs). 1,2-Bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)-tetra(acetoxymethyl)ester, an intracellular calcium chelator, suppressed both ionomycin-induced osteoclast formation in cocultures and expression of RANKL and OPG mRNAs in primary osteoblasts. Phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C, also stimulated osteoclast formation in these cocultures and the expression of RANKL and OPG mRNAs in primary osteoblasts. Protein kinase C inhibitors such as calphostin and staurosporin suppressed ionomycin- and PMA-induced osteoclast formation in cocultures and expression of RANKL and OPG mRNAs in primary osteoblasts. Ionomycin stimulated RANKL mRNA expression in ST2 and MC3T3-G2/PA6 cells, but not in MC3T3-E1 or NIH-3T3 cells. These effects were closely correlated with osteoclast formation in response to ionomycin in cocultures with these stromal cell lines. OPG strongly inhibited osteoclast formation induced by calcium-elevating compounds and PMA in cocultures, suggesting that RANKL expression in osteoblasts is a rate-limiting step for osteoclast induction. Forskolin, an activator of cAMP signals, also stimulated osteoclast formation in cocultures. Forskolin enhanced RANKL mRNA expression but suppressed OPG mRNA expression in primary osteoblasts. These results suggest that the calcium/protein kinase C signal in osteoblasts/stromal cells is the fourth signal for inducing RANKL mRNA expression, which, in turn, stimulates osteoclast formation.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
J.-B. O. Barbaroux, M. Beleut, C. Brisken, C. G. Mueller, and R. W. Groves
Epidermal Receptor Activator of NF-{kappa}B Ligand Controls Langerhans Cells Numbers and Proliferation
J. Immunol., July 15, 2008; 181(2): 1103 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. D Anastasilakis, D. G Goulis, S. A Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, and A. Avramidis
Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide
Eur. J. Endocrinol., March 1, 2008; 158(3): 411 - 415.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J.-M. Koh, Y.-S. Lee, C.-H. Byun, E.-J. Chang, H. Kim, Y. H. Kim, H.-H. Kim, and G. S. Kim
{alpha}-Lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor {kappa}B ligand/osteoprotegerin ratio in human bone marrow stromal cells
J. Endocrinol., June 1, 2005; 185(3): 401 - 413.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
H. Fukushima, E. Jimi, H. Kajiya, W. Motokawa, and K. Okabe
Parathyroid-hormone-related Protein Induces Expression of Receptor Activator of NF-{kappa}B Ligand in Human Periodontal Ligament Cells via a cAMP/Protein Kinase A-independent Pathway
Journal of Dental Research, April 1, 2005; 84(4): 329 - 334.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
N. Sato, N. Takahashi, K. Suda, M. Nakamura, M. Yamaki, T. Ninomiya, Y. Kobayashi, H. Takada, K. Shibata, M. Yamamoto, et al.
MyD88 But Not TRIF Is Essential for Osteoclastogenesis Induced by Lipopolysaccharide, Diacyl Lipopeptide, and IL-1{alpha}
J. Exp. Med., September 7, 2004; 200(5): 601 - 611.
[Abstract] [Full Text] [PDF]

Home page
 CROBMHome page
U. H. Lerner
NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION
Critical Reviews in Oral Biology & Medicine, March 1, 2004; 15(2): 64 - 81.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Suda, N. Udagawa, N. Sato, M. Takami, K. Itoh, J.-T. Woo, N. Takahashi, and K. Nagai
Suppression of Osteoprotegerin Expression by Prostaglandin E2 Is Crucially Involved in Lipopolysaccharide-Induced Osteoclast Formation
J. Immunol., February 15, 2004; 172(4): 2504 - 2510.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. J. Bergh, Y. Xu, and M. C. Farach-Carson
Osteoprotegerin Expression and Secretion Are Regulated by Calcium Influx through the L-Type Voltage-Sensitive Calcium Channel
Endocrinology, January 1, 2004; 145(1): 426 - 436.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Zhang, X. Feng, and J. M. McDonald
The Role of Calmodulin in the Regulation of Osteoclastogenesis
Endocrinology, October 1, 2003; 144(10): 4536 - 4543.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
G.E. Wise, Y. Ren, and S. Yao
Regulation of Osteoprotegerin Gene Expression in Dental Follicle Cells
Journal of Dental Research, April 1, 2003; 82(4): 298 - 302.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Q. Fu, R. L. Jilka, S. C. Manolagas, and C. A. O'Brien
Parathyroid Hormone Stimulates Receptor Activator of NFkappa B Ligand and Inhibits Osteoprotegerin Expression via Protein Kinase A Activation of cAMP-response Element-binding Protein
J. Biol. Chem., December 6, 2002; 277(50): 48868 - 48875.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society